期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

再论血管紧张素受体拮抗剂治疗心力衰竭的价值尚未确定 被引量：3

下载PDF
导出
摘要 我们曾经在2000年本刊第3期上撰文指出,血管紧张素Ⅱ受体拮抗剂(ARBs)在治疗慢性心力衰竭中的价值不能确定[1].两年过去了,一些新的研究,特别是缬沙坦心力衰竭试验(Val-HeFT)结果的公布,又一次引起人们的关注[2].
作者 施仲伟
机构地区 上海第二医科大学瑞金医院心脏科
出处 《中国医药导刊》 2002年第4期266-269,共4页 Chinese Journal of Medicinal Guide
关键词 血管紧张素受体拮抗剂 心力衰竭 ELITE试验 疗效 CHARM试验 Val-HeFT试验
分类号 R541.6 [医药卫生—心血管疾病] R972 [医药卫生—药品]
  • 相关文献

二级参考文献18

  • 1Pitt B，Segal R，Martinez FA，etal．Randomized trial of losartan versus captopril in patients over 65 with heart failure(Evaluation of Losartan in The Elderly Study，ELITE)．Lancet，1997, 349(9054): 747～752
  • 2Gary R,,Yusuf S.Overview of randomized trials of angiotensin-converting engyme in-hibitors on mortality and morbidity in patients with heart failure[].The Journal of The American Medical Association.1995
  • 3Cohn JN.Results of Val-HeFT trial[].rd AHA Meeting.
  • 4Mazayev VP,Fomina IG,Kazakov EN,et al.Valsartan in heart fail-ure patients previously untreated with an ACE inhibitor[].International Journal of Cardiology.1998
  • 5Swedberg K,Pfeffer M,Granger C,et al.For the CHARM pro-gramme investigators.Candesartan in heart failure: assessment of re-duction in mortality and morbidity (CHARM): rational and design[].Journal of Cardiac Failure.1999
  • 6Pitt B,Poole-Wilson P,Segal R,et al.Effects of losartan versus cap-topril on mortality in patients with symptomatic heart failure: ratio-nale, design and baseline characterlstics of patients in the losartan heart failure survival study-ELITE Ⅱ[].Journal of Cardiac Failure.1999
  • 7Califf RM,Cohn JN.Cardiac protection: Evolving role of angiotensionreceptor blocker[].AHJ.2000
  • 8Colucci WS,Packer M,Bristow MR,et al.Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure[].Circulation.1996
  • 9Bristow MR,Gilbert EM,Abraham WT,et al.Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure[].Circulation.1996
  • 10Whorlow SL,Krum H.Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure[].The American Journal of Cardiology.2000

共引文献54

同被引文献24

  • 1陈化,王登科,刘秀梅.厄贝沙坦与培哚普利治疗老年慢性心力衰竭疗效的对比研究[J].中华老年多器官疾病杂志,2002,1(3):197-199. 被引量：3
  • 2Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long - term Evaluation (SMILE) study investigators.The effect of the angiotensin - converting - enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med, 1995;332(2): 80- 85.
  • 3Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med, 1992;327(10) : 669 - 677.
  • 4Kober L, Torp- Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin - converting - enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction.New Engl J Med, 1995;333(25) : 1670- 1676.
  • 5The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.Lancet, 1993; 342(8875) : 821 - 828.
  • 6Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation, 1999; 100(9) : 1016 - 1030.
  • 7Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee,for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and mordility in higih - risk patients after acute myocardial infaretion: the OPTIMAAL randomized trial. Lancet,2002;360(9335) : 752- 760.
  • 8Dahlof B, Devereux RB, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : a randomized trial against atenolol. Lancet, 2002;359(9311): 995-1003.
  • 9Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in The Elderly Study, ELITE) Lancet, 1997; 349(9054) : 747 - 752.
  • 10Pitt B, Poole - Wilson PA, Segal R, et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study- - ELITE Ⅱ. J Cardiac Fail, 1999, 5(2): 146- 154.

二级引证文献6

中国医药导刊
2002年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部